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T
he new position statement of European 
Renal Best Practice (ERBP) reflects 
important changes but falls short of a 
fair assessment of information published 
since the previous report.1 We recently reviewed 
the pertinent literature and did not find a proven 
morbidity, mortality, or quality-of-life benefit of 
early dialysis initiation.2
The new guidelines were developed in response 
to the randomized controlled trial Initiating Dial-
ysis Early and Late (IDEAL). This study found 
no difference in survival in patients assigned to 
early versus late start of dialysis. The new Euro-
pean guidelines are unchanged from 2002, except 
for the issues discussed here.3
The new guidelines include preparation of 
patients for renal replacement therapy or con-
servative care before they become symptomatic. 
The rationale for this approach is the assumption 
that clinically important uremic symptoms were 
responsible for the early start in the majority of 
patients randomized to late dialysis initiation in 
IDEAL. ERBP concludes that creatinine-based 
measures of estimated glomerular filtration rate 
(eGFR) in predialysis patients are fundamentally 
flawed and thus invalidate the observational stud-
ies performed since 2002 relating higher starting 
eGFR to worse survival.2 The report ignores the 
observational study that showed potential harm 
of early hemodialysis initiation.4 Lastly, the new 
guidelines continue to promote early dialysis for 
diabetics and for patients with poor nutritional sta-
tus, neither of which has evidence-based support.2
The welcome changes in the updated 
guidelines include promotion of predialysis 
multidisciplinary clinics, and the use of renal 
function trajectory (4 ml/min/1.73 m2/y decline 
in Modification of Diet in Renal Disease (MDRD) 
eGFR) in the decision for dialysis preparation and 
initiation.2 The guidelines fall short of recom-
mending nondialytic multidisciplinary follow-up 
for elderly patients with a slow decline in renal 
function and high accompanying comorbidity, 
who may be more likely to die a non-uremic 
death before they will need dialysis.
Dialysis initiation for  ‘uremic’ symptoms and 
the IDEAL study
The new guidelines base much of their opinion 
on the 322 of 422 IDEAL study patients assigned 
to late start who started early. What do we learn 
from these patients? Firstly, it is wrong to extrap-
olate symptoms of uremia, and their relation to 
dialysis initiation and morbidity or mortality 
outcomes, from a study that was not designed to 
address these issues. Secondly, in the appendix 
to the IDEAL study, the reasons given for these 
protocol violations show possible inconsistency 
and unreliability. Of the 88 specified etiologies, 
fluid overload accounted for 28 and physician dis-
cretion 25. Malnutrition, the commonest reason 
for early start, was reported in only five patients.2 
Two patients started early because of improve-
ment in glomerular filtration rate (GFR), which 
is illogical. The 234 patients for whom ‘uremia’ 
was listed as the reason for early start need further 
examination. Life-threatening uremic complica-
tions including pericarditis, uremic encephalopa-
thy, and oligoanuria occur at very low levels of 
renal function. None of these closely followed 
patients was reported to have started dialysis with 
these symptoms.
One explanation for the crossovers is the 
influence of the 2002 European and 2005 Austra-
lian/New Zealand guidelines that recommended 
dialysis initiation early (over 10 ml/min/1.73 m2 
GFR) if there is any sign of malnutrition; both 
guidelines insisted that failure to initiate dialysis 
at a GFR level less than 6 ml/min/1.73 m2 could 
be dangerous.3 Since these guidelines were widely 
disseminated after the study design (which had 
occurred prior to 2000) and patient randomiza-
tion, the guidelines and not definitive uremic 
symptoms may explain much of the early start-
ing. Interestingly, 21 of the patients randomized to 
early start had their start delayed to allow arterio-
venous (AV) fistula access creation. A welcome 
recommend ation in the new guidelines is that 
with close follow-up, dialysis should be delayed, 
where possible, to allow treatment via an AV 
fistula access rather than a central venous catheter.
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The notion that the IDEAL study provides 
high-quality evidence that patients with chronic 
kidney disease will become symptomatic at 
a GFR of 9–6 ml/min/1.73 m2 is inconsistent 
with the guideline view that the Cockcroft–
Gault equation (used in the IDEAL study) 
should not be used when the GFR is less than 
30 ml/min/1.73 m2 or to determine the need for 
dialysis, and that nephrologists can ignore renal 
function on the basis of creatinine clearance or 
MDRD eGFR and base their decision on symp-
toms. At the levels of renal function at which the 
IDEAL crossovers started dialysis, symptoms of 
uremia are nonspecific and correlate highly with 
and often cannot be separated from associated 
comorbidity.2
The guidelines also state that this symptom-
based approach can be used in groups comparable 
to the IDEAL study participants, with an average 
age of 60 and with peritoneal dialysis used in over 
50%, and thus is not applicable to much of the 
international dialysis population, which is older 
and is treated with hemodialysis.
Dismissal of observational study data showing 
possible harm of early dialysis initiation
ERBP dismisses results of recent observational 
studies, including more than 1 million patients, 
that show a graded decrease in survival with 
higher dialysis-initiation MDRD eGFR levels.2 
Two studies emphasized the fact that patients 
with decreased muscle mass may have falsely 
high MDRD eGFRs versus 24-hour urine-based 
clearance measures.2 Both studies dealt with 
large peritoneal dialysis populations and had 
much lower starting GFR levels (6 ml/min/1.73 
m2) than more recent studies, and they found 
the highest GFR discrepancy in diabetic patients 
and patients with low serum albumin and low 
body mass index (<2.5 g/dl and 19.2 kg/m2, 
respectively). Since neither study found a sur-
vival benefit of a higher GFR based on 24-hour 
urine (early start), they cannot be used to jus-
tify dialysis initiation at GFR levels in the 15-ml/
min/1.73 m2 range.
Observational data: the only way to examine 
possible benefit or harm of early dialysis initiation
A lesson not discussed by the new guidelines 
is that, because of crossovers, the IDEAL study 
was not able to show a benefit or harm of early 
dialysis initiation on account of the small (1.8 ml/
min/1.73 m2) difference in MDRD eGFR in the 
early- versus late-start groups.
One study left out of the recent guidelines con-
cluded that early dialysis initiation in a hemo-
dialysis cohort may be harmful.4 This study 
examined a 1996–2006 US incident hemodialy-
sis population under age 65, with no reported 
comorbidities (except hypertension). In the sub-
set of this cohort with initial serum albumin of 
3.5 gm/dl or higher, the 1-year survival showed 
a corresponding decrease with higher starting 
eGFR, compared with late starts, who initiated 
dialysis at eGFR less than 5 ml/min/1.73 m2 
(Table 1). The fully adjusted first-year mortality 
hazard ratio relative to the late-start group was 
1.27, 1.53, and 2.18 for eGFR 5–9.9, 10–14.9, and 
>15 ml/min/1.73 m2, respectively.
An editorial on this study claimed that since 
the reporting of comorbidity may be as low as 
60%, the earlier-starting patients had misleading 
comorbidity information.3 Nevertheless, there is 
no reason to suspect that the lack of comorbidity 
reporting is higher at higher starting eGFR levels. 
Also, falsely high eGFRs are less likely in nondia-
betic patients with higher serum albumin levels.2
Although the results of this healthy-cohort 
observational study do not prove that early hemo-
dialysis initiation is harmful, neither do any of the 
results from all published studies, including the 
IDEAL study, and the studies using GFR measures 
based on 24-hour urine urea and/or creatinine 
clearance, show a benefit of early starting.
Table 1 | First-year mortality from 1996 to 2006 among nondiabetic US Renal Data System subjects 
less than 65 years old with ‘zero’ comorbidity and serum albumin greater than 3.5 g/dla
MDRD eGFRb First-year mortalityc No. of patients Hazard ratiod
<5 3.6 10,598 1.0
5–9.9 4.5 20,131 1.27
10–14.9 6.7 3993 1.53
≥15 12.5 943 2.18
USRDS 23.8
Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; USRDS, US Renal Data System. 
aData from ref. 4. 
bFour-variable equation; in ml/min/1.73 m2. 
cFirst-year unadjusted mortality. 
dFirst-year fully adjusted mortality hazard ratio, adjusted for age, ethnicity, sex, cause of renal failure, year of treatment, and 
hemoglobin level. 
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Early initiation for diabetics, for nutritional 
reasons, or for patients in whom close 
supervision is not feasible and uremic symptoms 
may be difficult to detect?
Review of the available literature on nutritional 
benefit of early dialysis initiation shows little sup-
port for this practice.2 The only positive results 
came from small, short-term studies. The large 
HEMO study showed deterioration of all nutri-
tional parameters over 3 years of follow-up in 
1846 prevalent patients. No study to date has 
shown benefit of early dialysis initiation for dia-
betic patients.2
The recommendation supporting the practice 
of preemptive dialysis for patients who cannot 
be closely followed could be obviated with well-
staffed multidisciplinary predialysis clinics to help 
deal with the social problems that would result 
in this practice. The ERBP recommendation of 
preemptive dialysis where uremic symptoms are 
difficult to detect makes no sense.
Residual renal function and the lower limit of 
renal function when asymptomatic patients 
must start dialysis
The report recognizes the benefit of residual 
renal function, which has survival, morbidity, 
and quality-of-life benefits.2 It fails to recog-
nize the likelihood of loss of perhaps 50% of a 
patient’s endogenous renal function 1 year after 
dialysis initiation. This loss is hard to justify for 
nonspecific uremic symptoms. The guidelines 
state that the recommendation of a lower limit 
for dialysis initiation of 6 ml/min/1.73 m2 is 
“made more vague” by available data.
In conclusion, the basing of the updated ERBP 
guidelines for dialysis initiation solely on the 
IDEAL study is short-sighted. The potential harm 
of early dialysis initiation must be considered. 
Unless there are definitive uremic symptoms, 
closely monitored end-stage renal failure patients 
should wait to initiate dialysis until they have lev-
els of residual renal function of 5–9 ml/min/1.73 
m2, or even lower if asymptomatic.
The decision to start dialysis must be individu-
alized, with input from multidisciplinary predi-
alysis clinics that educate patients regarding the 
advantages and disadvantages of dialytic therapy 
for their specific set of physical, social, and psy-
chological circumstances. Additional resources 
should be provided for frequent predialysis fol-
low-up and AV fistula access preparation, where 
appropriate, to avoid the excess mortality and 
hospitalizations related to central venous access 
dialysis initiation.5
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